Co-Authors
This is a "connection" page, showing publications co-authored by Paolo Maggi and Paolo Bonfanti.
Connection Strength
0.722
-
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. BMC Infect Dis. 2019 Jun 25; 19(1):555.
Score: 0.207
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
Score: 0.176
-
Factors associated with hospital admission for COVID-19 in HIV patients. AIDS. 2020 11 01; 34(13):1983-1985.
Score: 0.057
-
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiol. 2019 Jul; 42(3):150-155.
Score: 0.052
-
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
Score: 0.049
-
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infect Drug Resist. 2018; 11:615-623.
Score: 0.048
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.045
-
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? Clin Res Hepatol Gastroenterol. 2017 10; 41(5):e76-e79.
Score: 0.045
-
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study. J Hypertens. 2017 02; 35(2):409-416.
Score: 0.044